Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myelomaImpact of HSC dose on engraftment, safety, and immune reconstitution

Experimental Hematology

Volumn 28, Issue 7, 2000, Pages 858-870

  Michallet, Mauricette ^a   Philip, Thierry ^b   Philip, Irène ^b   Godinot, Hubert ^c,d   Sebban, Catherine ^b   Salles, Gilles ^d   Thiebaut, Anne ^a   Biron, Pierre ^b   Lopez, Francis ^c,d   Mazars, Philippe ^c,d   Roubi, Nora ^c,d   Leemhuis, Tom ^c,d   Hanania, Elie ^c,d   Reading, Christopher ^c,d   Fine, Gilbert ^c,d   Atkinson, Kerry ^c,d   Juttner, Chris ^c,d   Coiffier, Bertrand ^a   Fière, Denis ^a   Archimbaud, Eric ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b CENTRE LÉON BÉRARD   (France)

^c SyStemix International   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CD34+Thy1 hematopoietic stem cell autologous transplantation; Multiple myeloma

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THY 1 ANTIGEN; VINCRISTINE;

ADULT; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; CELL SORTER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENTARITY DETERMINING REGION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNITY; INFECTION; LEUKOCYTE COUNT; MALE; MULTIPLE MYELOMA; NEUTROPHIL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SAFETY; STEM CELL TRANSPLANTATION; TUMOR CELL; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, CD34; ANTIGENS, THY-1; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION;

EID: 0034125386     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00169-7     Document Type: Article

References (60)

1. Bell J.B.G., Maitland J.A., Gore M.et al. Increase in clonogenic tumor cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicine, and methylprednisolone. Lancet. 2:1988;931.
2. Dreyfus F., Melle J., Quarre M.C.et al. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high dose chemotherapy. Br J Haematol. 85:1993;411.
3. Abdou N.I., Abdou N.L. The monoclonal nature of lymphocytes in multiple myeloma. Ann Intern Med. 83:1985;42.
4. Mellstedt H., Hammarstrom S., Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol. 17:1974;371.
5. Pilarski L.M., Jensen G.S. Monoclonal circulating B cells in multiple myeloma. Hematol Oncol Clin North Am. 6:1992;297.
6. Lemoli R., Fortuna A., Motta M.et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients. positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Blood. 87:1996;1625.
7. Brenner M.K., Rill D.R., Moen R.C.et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85.
8. Deisseroth A., Zu Z.M., Claxton D.et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood. 83:1994;3068.
9. Rill D.R., Santana V.M., Roberts W.M.et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 84:1994;380.
10. Gregory W.M., Richards M.A., Malpas J.S. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma. an overview of published trials J Clin Onco. 1 10:1992;334.
11. Attal M., Harrousseau J.L., Stoppa A.M.et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 335:1996;91.
12. Vescio R.A., Han E.J., Schiller G.J.et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant. 18:1996;103.
13. Nizet Y., Martiat P., Vaerman J.L.et al. Follow-up of residual disease (MRD) in B lineage acute leukemias using a simplified PCR strategy. evolution of MRD rather than its detection is correlated with clinical outcome Br J Haematol. 79:1991;205.
14. Billadeau D., Quam L., Thomas W.et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 80:1992;1818.
15. Gazitt Y., Reading C., Hoffman R.et al. Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood. 86:1995;381.
16. Reece D.E., Barnett M.J., Connors J.M.et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant. 11:1993;139.
17. Anderson K., Barut B., Ritz J.et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 77:1991;712.
18. Vescio R., Hong C., Cao J.et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood. 84:1994;3283.
19. Willems P., Croockewit A., Raymakers R.et al. CD34 selection from myeloma peripheral blood cell autografts contain residual tumor cells due to impurity, not to CD34+ myeloma cells. Br J Haematol. 93:1996;613.
20. Brugger W., Henschler R., Heimfeld S.et al. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP-16, ifosfamide, carboplatin and epirubicin. Blood. 84:1994;1421.
21. Gorin N., Lopez M., Laporte J.et al. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood. 85:1995;1647.
22. Schiller G., Vescio R., Freytes C.et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood. 86:1995;390.
23. Civin C.I., Trischemann T., Kadan N.S.et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol. 14:1996;2224.
24. Takishita M., Kosaka M., Goto T.et al. Cellular origin and extent of clonal involvement in multiple myeloma. genetics and phenotypic studies Br J Haematol. 87:1994;735.
25. Belch A., Bergsagel P., Szcaepek A.et al. CD34+ cells in the blood of patients with multiple myeloma express clonotypic IgH sequences. Blood. 84(suppl. 1):1994;385. (abstr).
26. Spangrude G.J., Heimfeld S., Weissman I.L. Purification and characterization of mouse hematopoietic stem cells. Science. 241:1988;58.
27. Smith L.G., Weissman I.L., Heimfeld S. Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci U S A. 88:1991;2788.
28. Murray L., Chen B., Galy A.et al. Enrichment of human hematopoietic stem cell activity in the CD34+Thy1+Lin- subpopulation from mobilized peripheral blood. Blood. 85:1995;368.
29. Samson D., Gaminara E., Newland A.et al. Infusion of vincristine and doxorubicine with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 2:1989;882.
30. Alexanian R., Barlogie B., Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 33:1990;86.
31. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured MM cell mass with presenting clinical features, response to treatment and survival. Cancer. 36:1975;842.
32. Tricot G., Gazitt Y., Leemhuis T.et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood. 91:1998;4489.
33. Noga S.J., Davis J.M., Thoburn C.J.et al. Lymphocyte dose modification of the bone marrow allograft using elutriation. Gee A.P. Bone marrow Transplantation. 1991;CRC Press, Boca Raton. 175p.
34. Ishizawa L., Hangoc G., Van-de-Ven C.et al. Immunomagnetic separation of CD34+ cells from human bone marrow, cord blood, and mobilized peripheral blood. J Hematother. 2:1993;333.
35. Sasaki D.T., Tichenor E.H., Lopez F.et al. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. J Hematother. 4:1995;503.
36. Gerard C.J., Olsson K., Ramanathan R.et al. Improved quantitation of minimal residual disease in multiple myeloma using real-time PCR and plasmid-DNA CDRIII standards. Cancer Res. 58:1998;3957.
37. Tricot G., Jagannath S., Vesole D.et al. Peripheral blood stem cell transplant for multiple myeloma. identification of favorable variables for rapid engraftment in 225 patients Blood. 85:1995;588.
38. Haas R., Mohle R., Fruehauf S.et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 83:1994;3787.
39. Haas R., Witt B., Mohle R.et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cells in malignant lymphoma. Blood. 85:1995;3754.
40. Johnson R.J., Owen R.G., Smith G.M.et al. Peripheral blood stem cell transplantation in multiple myeloma using CD34 selected cells. Bone Marrow Transplant. 17:1996;723.
41. Lemoli R.M., Fortune A., Raspadori D.et al. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. Leuk Lymphoma. 26(suppl. 1):1997;1.
42. Vescio R, Schiller G, Stewart AK, et al. (1999) Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 93:1858.
43. Roots-Weiss A., Papadimitriou C., Serve H.et al. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems. Bone Marrow Transplant. 19:1997;1239.
44. Mossad S.B., Longworth D.L., Goormastic M.et al. Early infectious complications in autologous bone marrow transplantation. a review of 219 patients Bone Marrow Transplant. 18:1996;265.
45. Elishoov H., Or R., Strauss N.et al. Nosocomial colonization, septicemia and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. a 5-year prospective study Medecine. 77:1998;83.
46. Kolbe K., Domkin D., Derigs H.G.et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 19:1997;143.
47. Ottinger H.D., Beelen D.W., Scheulen B.et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 88:1996;2775.
48. Armitage R.J., Goldstone A.H., Richards J.D.M.et al. Lymphocyte function after autologous bone marrow transplantation (BMT). a comparison with patients treated with allogeneic BMT and with chemotherapy only Br J Haematol. 63:1986;637.
49. Storek J., Witherspoon R.P., Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 16:1995;413.
50. Henon PhR Liang H., Beck-Wirth G.et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow transplant. 9:1992;285.
51. Talmadge J.E., Reed E., Ino K.et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 19:1997;161.
52. Mackall C., Fleisher T., Brown M.et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 84:1994;2221.
53. Nordoy T., Husebekk A., Kolstad A. Persistent changes in the immune system 4-10 years post bone marrow transplantation. Consequences for the composition of the graft. J Hematother. 7:1998;276. (abstr).
54. Hokland M., Jacobsen J., Ellegaard J.et al. Natural killer function following allogeneic bone marrow transplantation. Very early reemergence but strong dependence of cytomegalovirus infection. Transplantation. 45:1988;1080.
55. Bengtsson M., Totterman T.H., Smedmyr B.et al. Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation. a prospective phenotypic study with 2/3-color FACS analysis Leukemia. 3:1989;68.
56. Guillaume T., Sekhavat M., Rubinstein D.B.et al. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukine-10 in delayed immune reconstitution. Cancer Res. 54:1994;3800.
57. Olsen G.A., Gockerman J.P., Bast R.C.et al. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation. 46:1988;57.
58. Lum L.G. Immune recovery after bone marrow transplantation. Hematol Oncol Clin North Am. 4:1990;659.
59. Bomberger C., Singh-Jairam M., Rodey G.et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood. 91:1998;2588.
60. Atkinson K., Biggs J.C., Downs K.et al. GM-CSF after allogeneic bone marrow transplantation. accelerated recovery of neutrophils, monocytes and lymphocytes Aust N Z J Med. 21:1991;686.